Forbes January 2, 2025
President-elect Donald Trump prides himself on making deals. Here is one for him: Keep Joe Biden’s commitment to have Medicare pay for GLP-1 drugs such as Ozempic and Wegovy for weight loss. But only if the drugmakers agree to substantially reduce their prices right away.
Such a move would be fraught for Trump and his Republican allies on multiple levels. But it presents the incoming president with a major political opportunity as well as some significant challenges. And not doing the deal brings its own risks.
The Backstory
While Medicare pays for the GLP-1 drugs for people with Type-2 diabetes and some forms of heart disease, it has been barred by an old federal law from paying for weight-loss drugs....
Today's Sponsors
Today's Sponsor